Thank you, Russell. We had a strong quarter and an excellent finish to 2024. Our organic sales growth was 1.6% this quarter. Our gross profit margin improved to 51.6%. We increased our investment in R&D, and we reduced SG&A as a percentage of sales. This resulted in earnings growth and another quarterly record GAAP EPS of $1.15 per share, which was up 15% compared to the fourth quarter of last year. Our non-GAAP EPS, which is calculated as our GAAP EPS, excluding the after-tax impact of amortization expense was $1.19 per share this quarter, which was up 14.4% over the fourth quarter of last year. Both regions performed well this quarter. Our Americas and Asia region grew organic sales 3.4%, and increased segment profit by 6.7%. Our Europe and Australia region declined 1.8% organically compared to last year's fourth quarter, which follows an impressive streak of 13 straight quarters of organic sales growth. The macro-environment in Europe has become more challenging over the last several months and quarters, but even despite the slight decline in organic sales, we were still able to increase operating income by 4.6% in the region, which was driven by continued improvement in gross profit margin and ongoing efficiency gains throughout our cost structure in Europe. The key financial takeaways this quarter are record high EPS, record high cash flow from operating activities, continued strong financial performance within both of our regions, and a continued commitment to return funds to our shareholders. Let's move to Slide number 4, for our quarterly sales trends. Organic sales grew 1.6% this quarter. The recent strengthening of the U.S. dollar versus other major currencies decreased sales by 0.8% and divestitures decreased sales by 1.5% for a total sales decline of 0.7% in the quarter. Moving to Slide number 5, you'll find our quarterly gross profit -- our gross margin trending. Our gross profit margin continues to be strong with an increase of 80 basis points to 51.6% compared to 50.8% in the fourth quarter of last year. We continue to realize benefits from our sales growth coming from higher gross profit margin products as well as stabilizing input costs compared to last year. Slide number 6, details our SG&A expense trending. SG&A was $93.3 million this quarter compared to $97.5 million in the fourth quarter of last year. As a percent of sales, SG&A declined to 27.2% compared to 28.2% of sales last Q4. And then, if you exclude amortization expense from each of the periods presented, then SG&A would have decreased from 27.5% of sales in the fourth quarter of last year to 26.5% of sales this quarter. We've made significant progress in optimizing our cost structure, reducing our SG&A expense from more than 36% of sales eight years ago to 28.1% in fiscal year 2024. At the same time, we've continued to invest in growth by expanding our sales force, enhancing our digital capabilities, and broadening our Omni channel strategies, all while identifying savings throughout our sales and other support functions. Moving to Slide number 7, you'll find the trending of our investments in research and development. This quarter, we once again increased our investment in R&D, finishing at $17.5 million, which was 5.1% of sales. We know that the investments with the best ROI are almost always organic investments and in particular our investments in research and development. We remain committed to new product development and we have another exciting lineup of products set to launch in fiscal 2025. On Slide number 8, you can see that pre-tax earnings increased 6.9% on a GAAP basis from $63.8 million to $68.2 million. And if you exclude amortization from both periods, pre-tax earnings increased 6.6% on a non-GAAP basis from $66.2 million to $70.5 million. Slide number 9, details the trending of earnings and EPS. Here you can see a clear trend of increasing earnings, and you can also see that the fourth quarter is our strongest quarter on record. On both a GAAP and a non-GAAP basis, our fourth quarter EPS was an all-time record high. This quarter's GAAP EPS increased 15% compared to last year, and if you exclude the after-tax impact of Amortization from both periods, our fourth quarter non-GAAP EPS increased 14.4% compared to last year. Turning to Slide number 10, you'll find a summary of our cash generation. Operating cash flow increased from $79.3 million in Q4 of last year to $84 million this quarter, and free cash flow continues to be strong at $73.2 million this quarter, compared to $73 million in last year's fourth quarter. Operating cash flow was 151% of net income and free cash flow was 132% of net income this quarter. Slide number 11, details the impact that our historical cash generation has had on our balance sheet. As of July 31, we were in a net cash position of $159.2 million. Our approach to capital allocation is consistent and -- which is to -- first, use our cash to fund organic sales growth and efficiency opportunities. This includes investing in new product development, sales generating resources, capability-enhancing CapEx and automation focused CapEx. We have the ability to continue to invest throughout the economic cycle so that we're always putting ourselves in the best position to drive future sales growth and profit growth. And second, we focus on consistently increasing our dividends. Yesterday, we announced our 39th consecutive year of annual dividend increases, which is a streak that we're very proud of. After funding organic investments and dividends, we then deploy our cash in a disciplined manner for acquisitions, where we have clear synergies, and then also for opportunistic share buybacks when we see a disconnect between intrinsic value and Brady's trading price. Our strong balance sheet puts us in a position to be able to continue to increase our investment in R&D and other organic sales opportunities to acquire companies strategically when the price is right, and to return funds to our shareholders through dividends and share buybacks. Slide number 12 provides an overview of our financial results for the full year ended July 31, 2024. Organic sales grew 2.6% and foreign currency translation increased sales 0.2% while the impact of divestitures decreased sales by 2.1% this year. We finished fiscal 2024 with all-time record high GAAP EPS and non-GAAP EPS. These strong earnings results were even after increasing our investment in R&D by more than 10% this year, resulting in the largest annual investment in R&D in company history. We're confident that our actions this year and our consistent priorities will set us up for success in the future, which takes us to our guidance for next year, which is shown on Slide number 13. We're forecasting GAAP EPS to range from $4.20 to $4.45 per share in fiscal 2025, which would represent an increase of between 2% and 9.3% compared to fiscal 2024. And we're forecasting non-GAAP EPS, which excludes the impact of amortization, to range from $4.40 to $4.70 per share in fiscal 2025, which would represent an increase of between 4.3% and 11.4%, compared to fiscal 2024. We also anticipate organic sales growth in the low-single digit percentages for the year ending July 31, 2025. Other elements of our guidance include an income tax rate of approximately 20%, depreciation and amortization expense of $38 million to $40 million, and capital expenditures of approximately $35 million. Potential risks to our guidance, among others, include potential strengthening of the U.S. dollar, inflationary pressures that we're unable to offset in a timely enough manner or an overall slowdown in economic activity. I'll now turn the call back over to Russell to cover our regional results and to provide some closing thoughts before Q&A. Russell?